Second-line treatment of small-cell lung cancer

  title={Second-line treatment of small-cell lung cancer},
  author={C. MacCallum and H. Gillenwater},
  journal={Current Oncology Reports},
  • C. MacCallum, H. Gillenwater
  • Published 2006
  • Medicine
  • Current Oncology Reports
  • Approximately 45,000 new cases of small-cell lung cancer were diagnosed in 2005 in the United States. Although response to first-time therapy is up to 90%, the majority of patients will ultimately relapse. Therefore, active second-line therapy is needed for this patient population. The only second-line treatment for small-cell lung cancer approved by the US Food and Drug Administration is topotecan. Other agents have been investigated and have shown modest efficacy. These include vinorelbine… CONTINUE READING
    23 Citations
    Topotecan in the treatment of relapsed small cell lung cancer
    • 8
    • PDF
    The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature
    • 4
    • Highly Influenced
    • PDF
    [Small cell lung cancer--state of the art and future perspectives].
    • 42
    • PDF
    Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.
    • 77


    Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan.
    • 23
    Chemotherapy of small cell lung cancer: state of the art
    • 26
    Options for first- and second-line therapy in small cell lung cancer--a workshop discussion.
    • 14
    Emerging role of weekly topotecan in recurrent small cell lung cancer.
    • 29
    Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study
    • 10
    Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.
    • 107
    Phase II study of imatinib in patients with small cell lung cancer.
    • 172
    • PDF